Ru-complex functionalized fungus-adherent upconversion nanosystem for NIR photodynamic anti-fungal therapy
Source abstract
Abstract
Fungal infections pose a severe global health threat, exacerbated by limited treatment options and increasing drug resistance. Ruthenium (Ru) complex based photodynamic therapy (PDT) presents a promising alternative that circumvents drug resistance, but its application has been constrained by poor tissue light penetration and limited accumulation within pathogens. To address these challenges, we developed a drug-loading core-shell nanosystem based on upconversion nanoparticles (UCNPs), designated as UCNP@dmSiO 2 -Ru, which integrates Yb/Tm-doped UCNPs with a polypyridine ruthenium (II) photosensitizer. Upon 980 nm irradiation, the UCNPs emit visible light that activates the ruthenium complex through energy transfer, resulting in localized singlet oxygen generation. In vitro , this nanoparticle could adhere to fungal cells, and demonstrated potent antifungal activity. In murine wound infection model, topical application followed by near-infrared light irradiation significantly accelerated the wound healing and reduced fungal burden, with no observable toxicity. This work provides a fungus-adherent PDT nanosystem with NIR-activation, overcoming the tissue penetration limitation and offering a promising strategy for treating deep-seated fungal infections.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Luminescence Properties of Advanced Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. New antifungal strategies and drug development against WHO critical priority fungal pathogens
2. Sati · 2022
3. Global and multi-national prevalence of fungal diseases-estimate precision10.3390/jof3040057 ↗
4. Tackling the emerging threat of antifungal resistance to human health10.1038/s41579-022-00720-1 ↗
5. What 'omics can tell us about antifungal adaptation10.1093/femsyr/foab070 ↗
6. Candida auris sp. Nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital10.1111/j.1348-0421.2008.00083.x ↗
7. Worsening spread of Candida auris in the United States, 2019 to 202110.7326/M22-3469 ↗
8. Reducing the off-target endocrinologic adverse effects of azole antifungals—can it be done?10.1016/j.ijantimicag.2022.106587 ↗
9. Review of pharmacologic considerations in the use of azole antifungals in lung transplant recipients10.3390/jof7020076 ↗
10. Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal10.1038/s41586-023-06710-4 ↗
11. Antimicrobial use of reactive oxygen therapy: current insights10.2147/IDR.S142397 ↗
12. Hot topics in reactive oxygen therapy: antimicrobial and immunological mechanisms, safety and clinical applications10.1016/j.jgar.2016.12.012 ↗
13. Photodynamic therapy for the treatment of fungal infections10.2147/IDR.S369605 ↗
14. Eradicating fungal biofilm-based infections by ultrasound-assisted semiconductor sensitized upconversion photodynamic therapy10.1038/s41467-025-61519-1 ↗
15. Controlling ground and excited state properties through ligand changes in ruthenium polypyridyl complexes10.1021/ic500408j ↗
16. Ru(II) polypyridyl complexes derived from tetradentate ancillary ligands for effective photocaging10.1021/acs.accounts.8b00066 ↗
17. Functionalization of a Ru(II) polypyridine complex with an aldehyde group as a synthetic precursor for photodynamic therapy10.1039/D5DT00256G ↗
18. Photodynamic inactivation of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus with Ru(II)-based type I/type II photosensitizers10.1016/j.pdpdt.2013.07.001 ↗
19. Ruthenium(II) polypyridyl complexes for antimicrobial photodynamic therapy: prospects for application in cystic fibrosis lung airways10.3390/pharmaceutics14081664 ↗
20. An aromatic ruthenium complex with high antimicrobial efficiency by disrupting biofilms and recruiting M2 macrophages10.1016/j.ica.2025.122546 ↗
21. Rationally designed ru(ii)-metallacycle chemo-phototheranostic that emits beyond 1000 nm10.1039/D2SC01518H ↗
22. Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods10.1007/s10103-017-2317-4 ↗
23. Light-activated antimicrobial polymers with citronellol-enhanced bacterial accumulation for on-demand disinfection10.1039/D5TB01507C ↗
24. NIR-triggered release of nitric oxide by upconversion-based nanoplatforms to enhance osteogenic differentiation of mesenchymal stem cells for osteoporosis therapy10.34133/bmr.0058 ↗
25. Core-shell structured upconversion nanocrystal-dendrimer composite as a carrier for mitochondria targeting and catalase enhanced anti-cancer photodynamic therapy10.1016/j.biomaterials.2020.119850 ↗
26. Cascade-responsive upconversion nanoplatform for efficient cell nucleus targeting and boosted photodynamic tumor therapy10.1021/acsmaterialslett.4c01614 ↗
27. Degradable calcium phosphate-coated upconversion nanoparticles for highly efficient chemo-photodynamic therapy10.1021/acsami.9b11973 ↗
28. Metabolic hijacking by engineered probiotics reprograms tumor metabolism and immune microenvironment for self-reinforcing photodynamic immunotherapy10.1021/jacs.5c10242 ↗
29. NIR-Light-Driven generation of reactive oxygen species using Ru(II)-Decorated lipid-encapsulated upconverting nanoparticles10.1021/acs.langmuir.9b01318 ↗
30. 808 nm NIR-triggered Camellia sapogein/curcumin-based antibacterial upconversion nanoparticles for synergistic photodynamic-chemical combined therapy
31. Multi-dimensional fluorescence lifetime and FRET measurements10.1002/jemt.20431 ↗
32. Derivatives of natural chlorophylls as agents for antimicrobial photodynamic therapy10.3390/ijms22126392 ↗
33. Effective treatment of systemic candidiasis by synergistic targeting of cell wall synthesis10.1038/s41467-025-60684-7 ↗
34. Phosphomannosylation and the functional analysis of the extended Candida albicans MNN4-Like gene family
35. Sialoglycoproteins in morphological distinct stages of Mucor polymorphosporus and their influence on phagocytosis by human blood phagocytes10.1007/s11046-013-9692-6 ↗
36. Antimicrobial peptides as anticancer agents: functional properties and biological activities10.3390/molecules25122850 ↗
37. Effective combinatorial antifungal therapy using a host defense peptide mimic that self-assembles into delivery micelles10.1038/s41587-025-02930-3 ↗
38. The wound healing potential of Lignosus rhinocerus and other ethno-myco wound healing agents10.1080/12298093.2022.2164641 ↗
39. Caged-hypocrellin mediated photodynamic therapy induces chromatin remodeling and disrupts mitochondrial energy metabolism in multidrug-resistant Candida auris10.1016/j.redox.2025.103708 ↗
40. An immunoconjugated up-conversion nanocomplex for selective imaging and photodynamic therapy against HER2-positive breast cancer10.1039/C8NR01512K ↗
41. Upconversion nanoparticles and its based photodynamic therapy for antibacterial applications: a state-of-the-art review10.3389/fchem.2022.996264 ↗
42. 80 years of extracellular vesicles: from discovery to clinical translation10.20517/evcna.2025.161 ↗
43. Unveiling the promise: exosomes as game-changers in anti-infective therapy10.1002/EXP.20230139 ↗
44. Engineering of monodisperse core-shell up-conversion dendritic mesoporous silica nanocomposites with a tunable pore size10.1039/C9NR10813K ↗